Comparative Pharmacology
Head-to-head clinical analysis: ZOMACTON versus ZORBTIVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZOMACTON versus ZORBTIVE.
ZOMACTON vs ZORBTIVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ZOMACTON is a recombinant human growth hormone that binds to growth hormone receptors on cell surfaces, activating intracellular signaling cascades (primarily JAK-STAT pathway) leading to increased IGF-1 production, which mediates growth and metabolic effects including linear growth, protein synthesis, and lipolysis.
Recombinant human growth hormone that binds to growth hormone receptors, activating JAK2/STAT5 signaling pathway, leading to increased IGF-1 production and promotion of linear growth.
Intramuscular or subcutaneous injection: 0.1-0.3 mg/kg/day (up to 0.6 mg/kg/day) divided into 1-2 doses. Typical adult dose for growth hormone deficiency: 0.2 mg/kg/day subcutaneously.
ZORBTIVE (somatropin) 0.006 mg/kg subcutaneously once daily for growth hormone deficiency in adults. Dose may be titrated based on clinical response and serum IGF-1 levels.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours after subcutaneous administration; clinically, this necessitates daily or more frequent dosing.
Terminal elimination half-life of ZORBTIVE is approximately 2.5 hours after subcutaneous administration. For intravenous administration, the half-life is shorter at 0.6 hours. The longer subcutaneous half-life reflects sustained absorption from the injection site.
Renal: nearly 100% of absorbed dose, mostly as intact hormone; negligible biliary/fecal elimination.
ZORBTIVE (somatropin) is eliminated primarily via the kidneys through glomerular filtration and tubular reabsorption. Approximately 70% of the dose is excreted renally as intact peptide, with 30% undergoing hepatic metabolism and biliary excretion. Fecal elimination accounts for less than 5%.
Category C
Category C
Growth Hormone
Growth Hormone